Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000814133-25-000031
Filing Date
2025-04-07
Accepted
2025-04-07 14:15:51
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4948
  Complete submission text file 0000814133-25-000031.txt   6834
Mailing Address 505 WAKARA WAY 3RD FLOOR SALT LAKE CITY UT 84108
Business Address 505 WAKARA WAY 3RD FLOOR SALT LAKE CITY UT 84108 8015330777
WASATCH ADVISORS LP (Filed by) CIK: 0000814133 (see all company filings)

EIN.: 870319391 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Subject) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87536 | Film No.: 25817579
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)